Samuel A. McMahon

Associate

Philadelphia
T +1.215.564.3297
F +1.215.568.3439

Overview

Sam’s background in biochemistry, cellular and molecular biology equips him with the necessary toolset to assist clients across a wide range of technologies within the chemical and life sciences. He has drafted and prosecuted U.S. and international patent applications directed to immunotherapies and other biologics, recombinant animal models, cosmetics and biomedical devices. Sam also has experience with patent litigation, competitor intellectual property landscape assessments, freedom to operate assessments and opinion preparation. He approaches every task with client objectives and expectations in mind, and he is motivated to develop efficient solutions for client needs.

Select Experience

  • Contributed to non-infringement and invalidity opinions for client seeking to launch new drug products, including analyzing competitor patent portfolios and opinion drafting.

  • Assisted in management of large international patent portfolios, including coordinating parallel patent prosecution in the United States and numerous foreign jurisdictions simultaneously.

  • Provided litigation assistance to a client asserting patent infringement of a pharmaceutical formulation patent, including providing legal research, drafting court-mandated submissions, attending court hearings and providing e-discovery support.

More »

Experience

  • Contributed to non-infringement and invalidity opinions for client seeking to launch new drug products, including analyzing competitor patent portfolios and opinion drafting.

  • Assisted in management of large international patent portfolios, including coordinating parallel patent prosecution in the United States and numerous foreign jurisdictions simultaneously.

  • Provided litigation assistance to a client asserting patent infringement of a pharmaceutical formulation patent, including providing legal research, drafting court-mandated submissions, attending court hearings and providing e-discovery support.

  • Drafted office action responses for U.S. and international patent applications in the life sciences, including biotech and biomedical device applications.

  • Drafted provisional and non-provisional patent applications for life sciences and biomedical devices.

  • Assisted inside counsel with preliminary due diligence and freedom to operate issues for both start-up and established life sciences companies.

Recognitions and Memberships

Community

  • Benjamin Franklin American Inn of Court (2016 to present)
  • Philadelphia Intellectual Property Law Association (2016 to present)
  • Bicycle Coalition of Greater Philadelphia (2016 to present)

Industries

Prior Positions

  • New Hampshire Supreme Court: Legal Intern (2016) 

Admissions

  • U.S. Patent and Trademark Office, Registration No. 74,865
  • Pennsylvania, 2016

Education

  • J.D., University of New Hampshire School of Law, 2016; Editor in Chief, IDEA: The Journal of The Franklin Pierce Center for Intellectual Property;Franklin Pierce Intellectual Property Law Certificate
  • M.S., Biochemistry Molecular Cellular Developmental Biology, University of California, Davis, 2013
  • B.S., M.S., Biotechnology, University of Nevada, Reno, 2009

Blog

In The Blogs

Previous Next
IP Intelligence: Insight on Intellectual Property
Regeneron Pharmaceuticals, Inc. v. Merus N.V.: The Federal Circuit Revisits the Defense of Inequitable Conduct
By Samuel A. McMahon
August 4, 2017
In Regeneron Pharmaceuticals, Inc. v. Merus N.V., No. 2016-1346, slip op. (Fed. Cir. July 27, 2017) (hereafter, “Slip Op.”), the Federal Circuit seems to have loosened the standards for finding a patentee culpable of inequitable conduct...
Read More ->
IP Intelligence: Insight on Intellectual Property
Supreme Court Announces ‘Uniform and Automatic’ Rule for Patent Exhaustion
By Samuel A. McMahon
June 1, 2017
The Supreme Court on Tuesday, May 30, issued an opinion in Impression Prods., Inc. v. Lexmark Int’l, Inc., No. 15–1189 (S. Ct. May 30, 2017), [hereafter “Lexmark”], reversing the Federal Circuit on two aspects of the patent exhaustion...
Read More ->
IP Intelligence: Insight on Intellectual Property
The Supreme Court Again Rejects Post-Expiration Patent Royalties
By Samuel A. McMahon
July 9, 2015
Authored by: Samuel McMahon, 2015 Summer Associate In Kimble v. Marvel Entertainment, LLC, No. 13-720 (U.S. June 22, 2015), the Supreme Court, in a 6-3 decision with Justice Kagan writing for the majority, upheld its 1964 decision in...
Read More ->